Moreover, relying solely on amyloid biomarkers for AD diagnosis is challenging due to AD's heterogeneous nature and its frequent co-occurrence with other pathologies like cerebrovascular lesions, Lewy bodies, and TDP-43 [24]. This evidence concerns the gene TARDBP and Alzheimer disease.